手机验证
/
Hepa-RG
/
充足
/
/
/
/
/
咨询客服
咨询客服
人
/
咨询客服
/
咨询客服
复苏发货或干冰冷冻发货
/
咨询客服
1 x 10^6 cells/vial/T25
细胞在发货前进行质检:
1、细胞存种的活性检测;
2、细菌、真菌、霉菌污染物镜检;
3、衣原体、支原体检测。
产品质量保证及售后:
1. 收到货后,请确认包装是否破损,细胞是否有异常,请在24h内及时联系客服,提供图片及相关资料,核实后,可直接免费重新补发;
2. 若发现细胞大部分死亡或细胞状态不佳的情况,请在收货后24h内反馈;受运输影响,签收的细胞状态不好,调养两三天没有改善的;若发现细胞有污染,应当在签收货物日起的7天内,可重新补发一株;售后时间为一周,仅限于细胞本身的质量问题,签收的细胞状态正常,后续因甲方培养体系或个人操作导致的细胞状态问题不在售后范畴。
3. 逾期15天内,重发仅收取耗材费和运费。30天内,重发收取半价;超过一个月重发全额收费。
4. 细胞鉴定异常,60天内反馈细胞鉴定不对,核实后,可免费退换货;
用户须知:
1、关于货期:除复苏细胞外,承诺货期1周内到(节假日顺延),大多数产品1-3天内发货。细胞产品因需要复苏后进行1-2代传代调整后等待细胞长满,期间进行微生物检测,货期1、2周左右。
2、关于订购:为了保证您的权益,下单前务必联系我司客户服务热线(021-55150076)。
联系人:胡经理
电话:15921028707(微信同号)
:3407506161
:021-55150076
官网:https://whelab.com
公司邮箱:info@whelab.com
技术邮箱:tech@whelab.com
地址:上海宝山区呼兰西路129号8号楼4层
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
PubMed=12432097; DOI=10.1073/pnas.232137699
Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C.
Infection of a human hepatoma cell line by hepatitis B virus.
Proc. Natl. Acad. Sci. U.S.A. 99:15655-15660(2002)
PubMed=17241619; DOI=10.1016/j.cbi.2006.12.003
Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C.
The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Chem. Biol. Interact. 168:66-73(2007)
PubMed=17393521; DOI=10.1002/hep.21536
Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A.
Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.
Hepatology 45:957-967(2007)
Patent=US7456018
Gripon P., Guguen-Guillouzo C., Trepo C., Rumin S.
Human hepatoma lines, methods for obtaining same and uses thereof.
Patent number US7456018, 25-Nov-2008
PubMed=20228232; DOI=10.1124/dmd.109.031831
Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.
A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.
Drug Metab. Dispos. 38:988-994(2010)
PubMed=20645056; DOI=10.1007/978-1-60761-688-7_13
Marion M.-J., Hantz O., Durantel D.
The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies.
Methods Mol. Biol. 640:261-272(2010)
PubMed=21414303; DOI=10.1016/j.bcp.2011.03.004
Ceelen L., De Spiegelaere W., David M., De Craene J., Vinken M., Vanhaecke T., Rogiers V.
Critical selection of reliable reference genes for gene expression study in the HepaRG cell line.
Biochem. Pharmacol. 81:1255-1261(2011)
PubMed=22568886; DOI=10.1517/17425255.2012.685159
Andersson T.B., Kanebratt K.P., Kenna J.G.
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.
Expert Opin. Drug Metab. Toxicol. 8:909-920(2012)
PubMed=22594799; DOI=10.3109/13813455.2012.683442
Huaman Samanez C., Caron S., Briand O., Dehondt H., Duplan I., Kuipers F., Hennuyer N., Clavey V., Staels B.
The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism.
Arch. Physiol. Biochem. 118:102-111(2012)
PubMed=22643240; DOI=10.1016/j.tiv.2012.05.008
Antherieu S., Chesne C., Li R.-Y., Guguen-Guillouzo C., Guillouzo A.
Optimization of the HepaRG cell model for drug metabolism and toxicity studies.
Toxicol. In Vitro 26:1278-1285(2012)
PubMed=22857383; DOI=10.1186/1477-5956-10-47
Sokolowska I., Dorobantu C.M., Woods A.G., Macovei A., Branza-Nichita N., Darie C.C.
Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells.
Proteome Sci. 10:47.1-47.13(2012)
PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)
PubMed=26160117; DOI=10.1093/toxsci/kfv136
Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.
Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.
Toxicol. Sci. 147:412-424(2015)
PubMed=26694163; DOI=10.1371/journal.pone.0144924
Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K., Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M., Giefing M., Jarmuz-Szymczak M.
Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma.
PLoS ONE 10:E0144924-E0144924(2015)
PubMed=27027780; DOI=10.1007/s10565-016-9316-2
Wu Y., Geng X.-C., Wang J.-F., Miao Y.-F., Lu Y.-L., Li B.
The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury.
Cell Biol. Toxicol. 32:37-59(2016)
PubMed=27169750; DOI=10.1038/srep24709
Sharanek A., Burban A., Burbank M., Le Guevel R., Li R., Guillouzo A., Guguen-Guillouzo C.
Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.
Sci. Rep. 6:24709-24709(2016)
PubMed=27780834; DOI=10.1124/dmd.116.072603
van der Mark V.A., de Waart D.R., Shevchenko V., Oude Elferink R.P.J., Chamuleau R.A.F.M., Hoekstra R.
Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells.
Drug Metab. Dispos. 45:56-67(2017)
PubMed=27975304; DOI=10.1007/978-1-4939-6700-1_2
Ni Y., Urban S.
Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and primary human hepatocytes.
Methods Mol. Biol. 1540:15-25(2017)
PubMed=28904299; DOI=10.2131/jts.42.641
Tomida T., Ishimura M., Iwaki M.
A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis.
J. Toxicol. Sci. 42:641-650(2017)
PubMed=30795634; DOI=10.3390/cells8020192
Tascher G., Burban A., Camus S., Plumel M.I., Chanon S., Le Guevel R., Shevchenko V., Van Dorsselaer A., Lefai E., Guguen-Guillouzo C., Bertile F.
In-depth proteome analysis highlights HepaRG cells as a versatile cell system surrogate for primary human hepatocytes.
Cells 8:192.1-192.25(2019)
PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)
PubMed=33441761; DOI=10.1038/s41598-020-79952-1
Heintze T., Klein K., Hofmann U., Zanger U.M.
Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.
Sci. Rep. 11:1000-1000(2021)
需要更多技术资料 索取更多技术资料
细胞售后说明.pdf 附 (下载 0 次)